Veteran amyloid champion helps Alzheimer's startup grab $160M in IPO as investors charge back in to a once faded field
The amyloid beta theory in Alzheimer’s research has staged a comeback with investors as well as the FDA.
Thursday morning Acumen Pharmaceuticals priced its upsized IPO at $16, hitting the high end of the range and scoring $160 million for the biotech.
Acumen pitched investors on the idea that the biotech offers a differentiated approach to amyloid, targeting soluble amyloid-beta oligomers, or AbOs, with its lead candidate ACU193.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.